Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Jun 14, 2016
Genomic Health Launches Oncotype SEQ™ Liquid Biopsy Mutation Panel
Genomic Health Provides Unique New Option for Non-invasive Tumor Assessment in Later-stage Disease, Transforming Cancer Care Across the Patient Journey
Jun 08, 2016
Nature Partner Journals Publish Five-year Outcomes Results from SEER Registry Demonstrating Oncotype DX® Accurately Identifies Early-stage Breast Cancer Patients with Excellent Survival
Study Showed Node-negative and Node-positive Patients with Low Oncotype DX® Breast Recurrence Score™ Results - the Vast Majority Treated without Chemotherapy - Had Excellent Breast Cancer Survival
Jun 05, 2016
Genomic Health Announces Multiple Oncotype DX® Presentations at ASCO 2016 Showcasing Industry-leading Commitment to Bringing Precision Medicine to Cancer Patients
Four New Analyses of SEER Registry Provide Additional Evidence that Oncotype DX Accurately Predicts Patient Outcomes in Node-negative and Node-positive Breast Cancer and Reinforce Its Value in Older Women
Oral Presentation Highlights Positive Impact Oncotype DX Has on Decision Making Process, Including in Node-positive Disease
May 31, 2016
Genomic Health to Present at Jefferies 2016 Healthcare Conference
REDWOOD CITY, Calif. , May 31, 2016 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole , Chief Operating Officer and Chief Financial Officer, will present at the Jefferies 2016 Healthcare Conference at the Grand Hyatt in New York City on Tuesday, June 7, 2016 at
May 26, 2016
Genomic Health Announces Presentation of Seven Oncotype DX® Studies at the 2016 American Society of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis
Presentations in Breast and Prostate Cancers Underscore Genomic Health's Industry-leading Commitment to Help Physicians and Patients Optimize Cancer Treatment Decisions
May 25, 2016
Genomic Health Announces Publication in Journal of Clinical Oncology Demonstrating Oncotype DX® Predicts Late Distant Recurrence in Breast Cancer
Findings Confirm that Oncotype DX May Help Identify Breast Cancer Patients with Greatest Potential to Benefit from Extended Hormonal Therapy
May 04, 2016
Genomic Health Reports Double-Digit Revenue and Test Growth in Announcement of First Quarter 2016 Financial Results
19% Increase in Revenue; 16% Increase in Tests Delivered
Unparalleled Prospective Outcomes Evidence Drives Further Growth in U.S. Invasive Breast Business; 16% Increase in Revenue and 11% Increase in Test Volume
Conference Call Today at 4:30 p.m. ET
May 03, 2016
Genomic Health to Present at Bank of America Merrill Lynch 2016 Health Care Conference
REDWOOD CITY, Calif. , May 3, 2016 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits , Chairman of the Board, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch 2016 Health Care Conference at the Encore at Wynn Las Vegas on
Apr 27, 2016
Genomic Health to Announce First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 4, 2016
REDWOOD CITY, Calif. , April 27, 2016 /PRNewswire/ --  Genomic Health, Inc.  (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Wednesday, May 4 at 4:30 p.m. Eastern Time to discuss its first quarter 2016 financial results.  The call and webcast will follow
Mar 11, 2016
Genomic Health Announces Five-year Outcomes from International 'PlanB' Study Demonstrating the Clinical Utility of Oncotype DX® in Node-positive and High-risk Node-negative Breast Cancer
One of the Largest Contemporary Adjuvant Breast Cancer Trials in Europe Shows that Patients with Low Oncotype DX® Scores Can Be Spared Chemotherapy Even When Traditional Factors Indicate Higher-Risk Disease